{"result": {"id": "0f62466e-6443-47fe-9a01-fb93b7043488", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>ACEI<|>organization<|>ACEI是一种血管紧张素转换酶抑制剂，用于治疗高血压和心血管疾病。\")\n##\n(\"entity\"<|>ARB<|>organization<|>ARB是一种血管紧张素受体阻滞剂，用于治疗高血压和心血管疾病。\")\n##\n(\"entity\"<|>氢氯噻嗪<|>organization<|>氢氯噻嗪是一种利尿剂，常用于治疗高血压和水肿。\")\n##\n(\"entity\"<|>氨氯地平<|>organization<|>氨氯地平是一种钙通道阻滞剂，用于治疗高血压和心绞痛。\")\n##\n(\"entity\"<|>醛固酮<|>organization<|>醛固酮是肾上腺皮质球状带分泌的盐皮质激素，在高血压及相关疾病中发挥重要作用。\")\n##\n(\"relationship\"<|>Α受体阻滞剂<|>高血压<|>Α受体阻滞剂适用于高血压合并多种临床情况。<|>8)\n##\n(\"relationship\"<|>阿利吉仑<|>高血压<|>阿利吉仑用于显著降低高血压患者的血压水平。<|>9)\n##\n(\"relationship\"<|>盐皮质激素受体拮抗剂(MRA)<|>高血压<|>MRA能降低血压、有效保护心肾功能。<|>8)\n##\n(\"relationship\"<|>醛固酮<|>盐皮质激素受体拮抗剂(MRA)<|>醛固酮通过与MR结合发挥作用，MRA阻断MR过度激活。<|>7)\n##\n(\"relationship\"<|>螺内酯<|>盐皮质激素受体拮抗剂(MRA)<|>螺内酯是一种非选择性甾体类MRA。<|>9)\n##\n(\"relationship\"<|>依普利酮<|>盐皮质激素受体拮抗剂(MRA)<|>依普利酮是一种甾体类MRA。<|>9)\n##\n(\"relationship\"<|>非奈利酮<|>盐皮质激素受体拮抗剂(MRA)<|>非奈利酮是首个上市的非甾体MRA。<|>9)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1751558736, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 455, "prompt_tokens": 2998, "total_tokens": 3453, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 2944}, "prompt_cache_hit_tokens": 2944, "prompt_cache_miss_tokens": 54}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 降压药使用 ,  但 α受体阻滞剂仍可在多种临床情况下发挥重要的治  疗作用 。该类药物适用于高血压合并良性前列腺增  生、原发性震颤、血糖或血脂异常、难治性高血压 ,也可  用于合并周围血管病、哮喘的患者 ;对于高血压急症、 原发性醛固酮增多症筛查、嗜铬细胞瘤术前的血压控  制等也具有重要的临床应用价值[281] 。少数患者可发  生体位性低血压 ,最好使用控释制剂 。普通片应在每  晚睡前服用 。体位性低血压者禁用 。心力衰竭患者  慎用。\n　　　(8)直接肾素抑制剂 :作用机制是直接抑制肾素 ,  继而减少 AngⅡ的产生 ,可显著降低高血压患者的血  压水平[282-283] 。其他主要包括降低 PRA、阻断肾素/肾  素原受体 ,减少细胞内 AngⅡ的产生 。 目前唯一使用  的该类药物是阿利吉仑 ,能够明显改善高血压合并蛋  白尿、LVH等器官损害[284-285] 。阿利吉仑与 ACEI或  ARB联合 ,虽能减轻醛固酮逃逸和增强临床疗效 ,但  增加了高钾血症、低血压和肾功能损害的风险[286-287] 。 该药可与氢氯噻嗪或氨氯地平安全联合使用 。最常见  的不良反应为皮疹、腹泻。\n　　　(9) 盐皮质激素受体拮抗剂(MRA) :醛固酮是肾 上腺皮质球状带主要分泌的盐皮质激素 ,其通过与盐 皮质激素受体(mineralocorticoid receptor,MR) 结合 , 在高血压及相关疾病中发挥重要作用 。醛固酮具有促 进肾脏保钠排钾作用 ,还可能介导和加速 AngⅡ的损 伤作用 ,促进血管炎症和纤维化[288] 。MRA 阻断 MR 过度激活 ,能降低血压、有效保护心肾功能。\n　　　MRA可分为甾体和非甾体两类 。 甾体类 MRA 包括螺内酯和依普利酮 , 与 MR蛋白结合不够稳定 , 不能完全阻断 MR的过度激活[288] 。螺内酯作为非选 择性甾体类的 MRA,还有抑制雄激素受体的作用 ,可 导致男性乳腺发育、勃起障碍以及女性月经不调等不 良反应[289] 。 甾体类的 MRA依普利酮通过结构优化 ,\n\n\n\n　提高了对 MR的选择性 ,但对 MR 的亲和力只有螺内 酯的 1/40;仍有相当部分肾功能不全患者出现高钾血 症 。非奈利酮为首个上市的非甾体 MRA,通过其侧 链使 MR的构象发生改变 , 与 MR蛋白稳定结合 ,具 有高 MR选择性、高 MR亲和力的特点[290-291]  。该药 对雄激素、糖皮质激素、孕酮和雌\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>Α受体阻滞剂<|>organization<|>Α受体阻滞剂是一种降压药，适用于高血压合并良性前列腺增生、原发性震颤、血糖或血脂异常、难治性高血压等临床情况。\")\n##\n(\"entity\"<|>阿利吉仑<|>organization<|>阿利吉仑是一种直接肾素抑制剂，用于降低高血压患者的血压水平，改善高血压合并蛋白尿、LVH等器官损害。\")\n##\n(\"entity\"<|>盐皮质激素受体拮抗剂(MRA)<|>organization<|>盐皮质激素受体拮抗剂(MRA)包括螺内酯和依普利酮，用于阻断MR过度激活，降低血压、保护心肾功能。\")\n##\n(\"entity\"<|>螺内酯<|>organization<|>螺内酯是一种非选择性甾体类MRA，具有抑制雄激素受体的作用，可能导致男性乳腺发育、勃起障碍等不良反应。\")\n##\n(\"entity\"<|>依普利酮<|>organization<|>依普利酮是一种甾体类MRA，通过结构优化提高了对MR的选择性，但对MR的亲和力较低。\")\n##\n(\"entity\"<|>非奈利酮<|>organization<|>非奈利酮是首个上市的非甾体MRA，具有高MR选择性和高MR亲和力的特点。\")\n##\n(\"relationship\"<|>阿利吉仑<|>ACEI或ARB<|>阿利吉仑与ACEI或ARB联合使用，虽能减轻醛固酮逃逸和增强临床疗效，但增加了高钾血症、低血压和肾功能损害的风险。<|>7)\n##\n(\"relationship\"<|>阿利吉仑<|>氢氯噻嗪或氨氯地平<|>阿利吉仑可与氢氯噻嗪或氨氯地平安全联合使用。<|>8)\n##\n(\"relationship\"<|>螺内酯<|>依普利酮<|>螺内酯和依普利酮都是甾体类MRA，但依普利酮通过结构优化提高了对MR的选择性。<|>6)\n##\n(\"relationship\"<|>非奈利酮<|>螺内酯<|>非奈利酮是首个上市的非甾体MRA，与螺内酯相比具有高MR选择性和高MR亲和力的特点。<|>7)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": 4000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_a5220e725549e0d29215e886f8d8d6d2e29085276eab74f35d2c9cc9491b9c45_v2"}